Compounds > 4-aminopyridine-3-methanol
Page last updated: 2024-11-12

4-aminopyridine-3-methanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-aminopyridine-3-methanol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-aminopyridine-3-methanol : An aminopyridine that is 4-aminopyridine which is substituted by a hydroxymethyl group at position 3. It is a potassium channel blocker which restores axonal conduction after spinal cord injury. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10796739
CHEBI ID149772
SCHEMBL ID1930789
MeSH IDM0544867

Synonyms (27)

Synonym
138116-34-4
4-aminopyridine-3-methanol
(4-aminopyridin-3-yl)methanol
(4-amino-pyridin-3-yl)-methanol
FT-0655323
4-ap-3-meoh
4-amino-3-(hydroxymethyl)pyridine
4-amino-3-pyridinemethanol ,
CHEBI:149772
AKOS005255261
PB14435
3-pyridinemethanol, 4-amino-
AM20120561
WNBVEYMTVDMSFZ-UHFFFAOYSA-N
4-amino-3-hydroxymethylpyridine
SCHEMBL1930789
W-205513
TS-01636
(4-amino-3-pyridinyl)methanol
DTXSID10444916
(4-amino-pyridin-3-yl)-methanol, aldrichcpr
mfcd06203066
CS-0044077
(4-amino-pyridin-3-yl)methanol
3-(4-hydroxyphenyl)propionicacidn-hydroxysuccinimideester
nsc790506
nsc-790506
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
potassium channel blockerAn agent that inhibits cell membrane glycoproteins that are selectively permeable to potassium ions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
aminopyridineCompounds containing a pyridine skeleton substituted by one or more amine groups.
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
aromatic primary alcoholAny primary alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.36 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-aminopyridine
[no description available]		2.5520aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker
acrolein
[no description available]		2.1310enalherbicide;
human xenobiotic metabolite;
toxin
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		3.3660
myelin oligodendrocyte glycoprotein (35-55)
[no description available]		2.0610
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.8130
Injuries, Spinal Cord
[description not available]		02.8330
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).		02.8330
Conus Medullaris Syndrome
[description not available]		02.110
MS (Multiple Sclerosis)
[description not available]		02.0610
Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)		07.0610